Drug intelligence / Profile preview

RMSP1

Development stage: Preclinical
Lead developer: REMEDI
Modality: Peptides
Administration: Topical

Overview

RMSP1 is a preclinical peptide-based therapy developed by Remedi for the treatment of atopic dermatitis. It is a dual-functional peptide derived from the Speckled protein (SP) family, combining cell-penetrating peptide (CPP) properties with anti-inflammatory activity. Utilizing Remedi's proprietary intra-dermal delivery technology (IDDT) platform, RMSP1 is designed to penetrate cells and inhibit the NF-κB and STAT3 signaling pathways, thereby reducing the inflammatory response associated with skin conditions.

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)NF-κB

Beyond the preview

Go deeper on RMSP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMSP1.

Explore the full profile